<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Caesar&#8217;s</title>
	<atom:link href="http://www.tapanray.in/tag/caesars/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>‘Herceptin Biosimilars’ Seriously Questioned</title>
		<link>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=herceptin-biosimilars-seriously-questioned</link>
		<comments>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/#comments</comments>
		<pubDate>Fri, 07 Feb 2014 11:17:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[canmab]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CTRI]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hertaz]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[questioned]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[wife]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4969</guid>
		<description><![CDATA[The news struck as an anticlimax, close on the heels of high decibel product launch of ‘Herceptin Biosimilars’ in India, being hyped as the first in the world, bringing much needed relief to many diagnosed breast cancer patients for their &#8230; <a href="http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Innovation Absolutely Critical: But NOT Shorn from Ethics, Propriety, Compliance and Values</title>
		<link>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values</link>
		<comments>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/#comments</comments>
		<pubDate>Mon, 20 May 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[bribing]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[buzzword]]></category>
		<category><![CDATA[Caesar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[concealment]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[corrupt]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[denigrating]]></category>
		<category><![CDATA[developed world]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[fines]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[globalized]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grease]]></category>
		<category><![CDATA[guy]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[isolation]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lower]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[overcharging]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[propriety]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[spiritual]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[walk]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wife]]></category>
		<category><![CDATA[X factors]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2481</guid>
		<description><![CDATA[Significant value added innovation is the bedrock of progress of the pharmaceutical industry and is essential for the patients. This is a hard fact. However, this current buzzword – ‘innovation’ can in no way be shorn from soft business necessities &#8230; <a href="http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
